Financial Engines Advisors L.L.C. Reduces $601K in Abbott Laboratories ($ABT)
The firm reduced its position by over 21%, reflecting a strategic shift.
Key Points
- Financial Engines Advisors reduced its stake in Abbott Laboratories by 21.6%, selling 6,453 shares to hold 23,405 shares as of the latest filing.
- Abbott Laboratories trades at $89.77, with a market cap of approximately $157.8 billion and a forward P/E of 14.96.
- Analysts maintain a 'buy' consensus with a target mean price of $116.54, supported by recent insider buying activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Financial Engines Advisors L.L.C. has reduced its position in Abbott Laboratories (NYSE: ABT) by 21.6%, according to its latest 13F filing with the SEC. The firm sold 6,453 shares during the period, leaving it with 23,405 shares valued at about $2.1 million.
What Changed in Financial Engines Advisors' Abbott Laboratories Position
Financial Engines Advisors trimmed its holdings in Abbott Laboratories, moving from 29,858 shares to 23,405 shares. The reduction of 6,453 shares represents a 21.6% decrease, as per the filing reflecting holdings at the end of the quarter.
Other Institutional Activity in Abbott Laboratories
Several other major institutional investors have also adjusted their positions in Abbott Laboratories. BlackRock, Inc. reduced its holdings by 1,221,310 shares, ending with 145,687,458 shares valued at approximately $14.96 billion. Capital Research Global Investors increased its stake significantly by 10,606,123 shares, bringing its total to 49,775,362 shares worth about $5.11 billion. Meanwhile, Charles Schwab Investment Management Inc. saw a dramatic increase, adding 32,310,527 shares to hold 45,500,055 shares valued at around $4.67 billion.
Abbott Laboratories Stock Down 15.7%
Shares of Abbott Laboratories are currently trading at $89.77. The company, with a market cap of about $157.8 billion, has a P/E ratio of 25.38 and a forward P/E of 14.96. Abbott's stock has ranged between $81.97 and $139.06 over the past 52 weeks, with a 50-day moving average of $90.70 and a 200-day moving average of $114.07. The company maintains a current ratio of 1.39 and a quick ratio of 0.84, alongside a debt-to-equity ratio of 64.77.
$ABT stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Abbott Laboratories reported a revenue of $45.13 billion, reflecting a growth of 7.8%. The company's net margin stands at 13.9%, with a return on equity of 12.33%. Earnings per share were $3.57. The next earnings report is expected on July 16, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Abbott Laboratories offers an annual dividend rate of $2.52, yielding 2.78%. The payout ratio is 67.23%, indicating a stable dividend policy.
Insider Buying and Selling at Abbott Laboratories
Recent insider activity at Abbott Laboratories included several purchases. Executive Vice President Mary Moreland bought 5,314 shares at an average price of $94.41 on April 28, 2026. Daniel Starks acquired 10,000 shares at $92.65 on April 27, 2026. Other insiders such as Nita Ahuja and Sally Blount also made smaller purchases, further indicating insider confidence.
Analysts Set New Price Targets
On April 20, 2026, Barclays maintained its 'buy' rating for Abbott Laboratories with a price target of $143. Other firms like Piper Sandler and Oppenheimer also maintained 'buy' ratings with price targets of $115. Overall, the consensus among 24 analysts is a 'buy' recommendation with a target mean price of $116.54.
About Abbott Laboratories
Abbott Laboratories, headquartered in Abbott Park, Illinois, is a global healthcare company that develops and sells a wide range of medical devices and health care products. The company operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. With a workforce of 122,000 employees, Abbott provides products ranging from generic pharmaceuticals to nutritional products and medical devices.
Bottom Line
Financial Engines Advisors' decision to cut its stake in Abbott Laboratories by over 21% reflects a strategic portfolio adjustment. Investors continue to watch Abbott's performance closely, given its strong market position in the healthcare sector and its consistent dividend payouts. While 13F filings are backward-looking, they provide valuable insights into institutional investment trends.
Get Abbott Laboratories alerts
New 13F filings, insider trades, and analyst moves on $ABT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.